XNAS · Healthcare · Biotechnology
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.93 | -0.86 | +7.53% | $0 | ✅ Beat | +0.21% | +5.80% | — |
| 2026-03-25 | Q4 2025 | -1.03 | -0.73 | +29.13% | $0 | ✅ Beat | -2.01% | +2.46% | +9.81% |
| 2025-11-12 |
| Q3 2025 |
| -0.99 |
| -0.78 |
| +21.21% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | -0.87 | -0.93 | -6.90% | $0 | ❌ Miss | -0.25% | -2.91% | +5.82% |
| 2025-05-14 | Q1 2025 | -0.86 | -0.81 | +5.81% | $0 | ✅ Beat | — | — | — |
| 2025-03-31 | Q4 2024 | -0.67 | -0.75 | -11.94% | $0 | ❌ Miss | — | — | — |
| 2024-11-14 | Q3 2024 | -0.70 | -0.65 | +7.14% | $0 | ✅ Beat | — | — | — |
| 2024-08-14 | Q2 2024 | -0.68 | -0.58 | +14.71% | $0 | ✅ Beat | — | — | — |
Showing last 8 quarters.